Cure8 trial brief
Why This Matters
Understanding how patient-derived epithelial cells respond to inflammation could reveal mechanisms of poor mucosal healing in IBD and identify targets or biomarkers to improve repair. Organoid models from patient tissue may better reflect human epithelial biology than mouse models.
Who Should Pay Attention
researchers;clinicians;adult-patients;patients-on-biologics
Study Snapshot
What To Know
This is a registered interventional study (NCT06805890) recruiting adults to collect intestinal biopsies and resection samples from IBD patients and controls to grow patient-derived digestive organoids and study epithelial repair.
The primary aim is to compare the repair capacity of epithelial cells from inflamed versus non‑inflamed mucosa and controls using organoid assays and ex vivo tissue analyses.
The study will expose organoids to pro-inflammatory cytokines and luminal metabolites, measure proliferation, survival, metabolic activity, stem/differentiated cell balance, activation of cell‑death and protective pathways, and compare tissue hallmarks of repair with local inflammation and metabolite levels.
Keep In Mind
This is a registered interventional clinical study (recruiting) describing planned experiments and sample collection; it does not present outcomes or conclusions. Results will need peer-reviewed publication.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.